Assessment of immunogenicity and protective efficacy of ZyCoV-D DNA vaccine candidates in Rhesus macaques against SARS-CoV-2 infection

  title={Assessment of immunogenicity and protective efficacy of ZyCoV-D DNA vaccine candidates in Rhesus macaques against SARS-CoV-2 infection},
  author={Pragya Dhruv Yadav and Sanjay Kumar and Kshitij Agarwal and Mukul R Jain and Dilip R Patil and Kapil Maithal and Basavaraj Mathapati and Suresh R. Giri and Sreelekshmy Mohandas and Anita M. Shete and Gajanan N. Sapkal and Deepak Y. Patil and Ayan Dey and Harish Chandra and Gururaj R. Deshpande and Nivedita Gupta and Dimpal A. Nyayanit and Himanshu Kaushal and Rima R Sahay and Anuradha S. Tripathy and Rajlaxmi Jain and Abhimanyu Kumar and Prasad Sarkale and Shreekant Baradkar and Chozhavel TM Rajanathan and Hari Prasad Raju and Satish D. Patel and Niraj James Shah and Pankaj Dwivedi and Dharmendra Prasad Singh and Priya Abraham},
Vaccines remain the key protective measure to achieve herd immunity to control the disease burden and stop COVID-19 pandemic. We have developed and assessed the immunogenicity and protective efficacy of two formulations (1mg and 2mg) of ZyCoV-D (a plasmid DNA based vaccine candidates) administered through Needle Free Injection System (NFIS) and syringe-needle (intradermal) in rhesus macaques with three dose vaccine regimens. The vaccine candidate 2mg dose administered using Needle Free… 
Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models
Preliminary animal study demonstrates that the candidate DNA vaccine induces antibody response including neutralizing antibodies against SARS-CoV-2 and also provided Th-1 response as evidenced by elevated IFN-γ levels.
Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms
The considerable immunological aspects, potential antigen targets, appropriate adjuvants as well as key points in the various stages of COVID-19 vaccine development are introduced and the principal features of the preclinical and clinical studies of pioneering COVID -19 vaccine candidates were pointed out.
Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges
The emergence of a novel coronavirus viz., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in late 2019 and its subsequent substantial spread produced the coronavirus disease 2019
Covid‐19 vaccines and variants of concern: A review
The most relevant mutations in the SARS-CoV-2 spike protein are described, VE against VOCs is discussed, and additional effective vaccines are still needed to meet the global demand.
A brief review on DNA vaccines in the era of COVID-19
This article provides a brief overview of DNA vaccines. First, the basic DNA vaccine design strategies are described, then specific issues related to the industrial production of DNA vaccines are
A detailed review of the outbreak of COVID-19.
The fatality rate is high, but now is reduced after the development of preventive vaccine although an effective treatment by drug against the virus is yet to be developed, and social distancing has emerged as a putative method to decrease the rate of infection.
Human vaccines & immunotherapeutics: news
  • Medicine
    Human vaccines & immunotherapeutics
  • 2021
Fecal microbiota transplantation into melanoma immunotherapy non-responders improved treatment outcomes in two Phase 1 trials and was safe and well tolerated in both trials, neither of which included a control group.
COVID-19: comprehensive review on mutations and current vaccines
Viral outbreaks had been a threat for the human race for a long time. Several epidemics and pandemics have been reported in the past with serious consequences on human health and subsequent social


Remarkable immunogenicity and protective efficacy of BBV152, an inactivated SARS-CoV-2 vaccine in rhesus macaques
Data from this study substantiate the immunogenicity of the vaccine candidates and BBV152 is being evaluated in Phase I clinical trials in India (NCT04471519).
Soluble Spike DNA vaccine provides long-term protective immunity against SAR-CoV-2 in mice and nonhuman primates
It is indicated that GX-19 vaccination provides durable protective immune response and also support further development of G X-19 as a vaccine candidate for SARS-CoV-2 in human clinical trials.
Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model
These studies support the immune impact of INO-4800 for inducing both humoral and cellular arms of the adaptive immune system which are likely important for providing durable protection against COVID-19 disease.
Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates
These findings highlighted onset of quick immunogenicity and protective efficacy of mRNA-1273, followed by Ad26.CoV2.S, NVX-CoV2373, BNT162b2, RBD and BBV152 vaccine candidates in preclinical trials as compared to the others.
Development of an inactivated vaccine candidate for SARS-CoV-2
Preclinical results of an early vaccine candidate called PiCoVacc, which protected rhesus macaque monkeys against SARS-CoV-2 infection when analyzed in short-term studies, support the clinical development and testing of Pi coVacc for use in humans.
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
Analysis of the vaccine candidates in rhesus macaques showed that animals developed protective humoral and cellular immune responses when challenged with the SARS-CoV-2 virus, suggesting an immune correlate of protection.
Humoral and Cellular Immune Responses Induced by 3a DNA Vaccines against Severe Acute Respiratory Syndrome (SARS) or SARS-Like Coronavirus in Mice
This study provides a reference for designing cross-protective DNA vaccines based on the group-specific ORFs of CoVs and shows that high levels of specific humoral responses were induced by SARS-CoV 3a and SL-Cov 3a DNA vaccines.
Immunogenic Potential of DNA Vaccine candidate, ZyCoV-D against SARS-CoV-2 in Animal Models
Preliminary animal study demonstrates that the candidate DNA vaccine induces antibody response including neutralizing antibodies against SARS-CoV-2 and also provided Th-1 response as evidenced by elevated IFN-γ levels.
DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial
DNA vaccination by Biojector® was well-tolerated and compared to needle injection, primed for greater IFN-γ ELISpot, CD8+ T-cell, and antibody responses after rAd5 boosting.
A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates
It is demonstrated that a consensus MERS spike protein synthetic DNA vaccine can induce protective responses against viral challenge, indicating that this strategy may have value as a possible vaccine modality against this emerging pathogen.